Neil M. Bressler, MD
James P. Gills Professor of Ophthalmology
Professor of Ophthalmology, Johns Hopkins University School of Medicine
Wilmer Eye Institute, Johns Hopkins Medicine
A. Paul Chous, MA, OD, FAAO
Specializing in Diabetes Eye Care & Education, Chous Eye Care Associates
Adjunct Professor of Optometry, Western University of Health Sciences
AOA Representative, National Diabetes Education Program
Steven Ferrucci, OD, FAAO
Chief of Optometry, Sepulveda VA Medical Center
Professor, Southern California College of Optometry at Marshall B. Ketchum University
Julia A. Haller, MD
Wills Eye Hospital
Allen C. Ho, MD, FACS
Director, Retina Research
Wills Eye Hospital
Professor and Chair of the Department of Ophthalmology
Thomas Jefferson University Hospitals
Charles C. Wykoff, MD, PhD
Director of Research, Retina Consultants of Houston
Associate Professor of Clinical Ophthalmology
Blanton Eye Institute & Houston Methodist Hospital
RELIEF: A Vision Preservation and Blindness Prevention Initiative
Diabetic retinopathy (DR) is the leading cause of acquired blindness in the U.S. in patients aged 20 to 74 years. DR is a highly specific complication of both type 1 and type 2 diabetes, with its prevalence strongly correlating to both the duration of diabetes and level of glycemic control. In the U.S., DR affects approximately 86% of patients with type 1 diabetes mellitus (T1DM) and 40% of patients with type 2 diabetes mellitus (T2DM), and according to the Centers for Disease Control and Prevention (CDC), nearly 22% of the 4.1 million Americans with DR are at risk for vision-threatening complications.
The understanding of diabetic retinopathy (DR) has advanced markedly over the past few years. DR can be divided into 2 stages: non-proliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR). With increasing severity, there is increased vascular permeability and occlusion with progression from moderate and severe NPDR to PDR, characterized by the growth of new retinal and vitreal blood vessels. Research in DR has been followed by the development of an ever-expanding number of therapeutic agents to maintain normal, healthy vasculature in the eye and prevent this vascular permeability and the growth of retinal and vitreal blood vessels associated with DR.
The RELIEF initiative is an online learning tool for clinicians and patients interested in the management of DR in patients with diabetes who have or are at risk of developing DR. By compiling up-to-date information on the presentation, prognosis, pathophysiology, and treatment options for DR, we aim to provide users with a convenient resource that improves clinical outcomes and quality of life for patients. Our goal is to empower healthcare providers to personalize therapy based on therapeutic response and patient-specific factors through their participation in our online offerings and exploration of the Clinician Toolkit. Our Patient Toolkit is a handy resource that educates patients about their disease and empowers them to engage in their healthcare decisions.
Thank you for visiting our website. Please explore the Clinician Toolkit and Patient Toolkit links for cutting-edge information on current and emerging treatments for DR.
Med Learning Group
Med Learning Group, a division of Ultimate Medical Academy, is a full-service, accredited medical education company. Med Learning Group focuses on developing and implementing continuing education that improves healthcare practitioners’ ability to provide optimal care to their patients. Our goal is to provide high-quality education that is designed to deliver the highest level of outcomes for both the patient and the practitioner.